Ocular Surface

What happens when we have tried just about everything to treat their ocular surface disease? As testing strategies for ocular surface disease continues to evolve, our understanding of the underlying causes lead us to enhance our treatment guidelines. The goal of this course will be to discuss new and emerging ocular surface disease treatments and who might benefit within different patient populations.

Santen

RVL Pharmaceuticals

Thea

Aldeyra Therapeutics

Visus Therapeutics

Orasis Pharmaceuticals

Bruder

Tarsus Pharmaceuticals

Claris Bio

Avellino Labs

Alcon

Glaukos

Ocular Therapeutix

Viatris

Dompe

Allergan, an AbbVie company

Sight Sciences

Bausch + Lomb

Johnson & Johnson Vision

Cecelia Koetting, OD, FAAO

This course has been peer-reviewed by The University of Alabama at Birmingham.

EYES ON DRY EYE 2023 PRESENTS: The Most Promising Treatments in the OSD Pipeline

treatment